Reuters logo
BRIEF-Agile Therapeutics announces results of its pre-submission meeting with FDA
April 11, 2017 / 11:31 AM / 5 months ago

BRIEF-Agile Therapeutics announces results of its pre-submission meeting with FDA

April 11 (Reuters) - Agile Therapeutics Inc

* Agile Therapeutics announces results of its pre-submission meeting with FDA

* Agile Therapeutics Inc- It has received final meeting minutes from its recent new drug application

* Agile Therapeutics Inc - FDA indicated that based on preliminary information provided by company, secure trial results appear acceptable for resubmission

* Agile Therapeutics - Has necessary information to complete resubmission of NDA, which is expected to be submitted by end of Q2 of 2017 for Twirla

* Agile Therapeutics - FDA did not provide feedback on if results of secure trial and contents resubmitted NDA will be sufficient for approval of Twirla Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below